Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomas

Clinical study of gemcitabine plus docetaxel in patient with refractory bone and soft tissue sarcomas - GEM+DTX in patient with sarcomas

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017967

Enrollment

Registered

2015-06-25

Start date

2015-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone and soft tissue sarcoma

Interventions

From June 25th, 2015 to December 31th, 2018 Gemcitabine675mg/m2, day1, day8 Docetaxel75mg/m2, day8 3 weeks or more interval

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Establishment of histopathological diagnosis of bone and soft tissue sarcomas Non responder case with previous 1st line chemotherapy Patient who had enough understanding after explanation of this study and presented document of agreement by their free will

Exclusion criteria

Exclusion criteria: Patient with severe liver or renal dysfunction Patient with severe interstitial pneumonitis PS4 Pregnant woman Patient who was decided as incompatible by the principal investigator of this study

Design outcomes

Primary

Measure	Time frame
tumor response survival	—

Countries

Japan

Contacts

Public ContactTorigoe Tomoaki

Juntendo University Urayasu Hospital Orthopaedic Surgery

ttorigoe@juntendo.ac.jp047-353-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026